{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:11:56Z","timestamp":1790413916892,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>Type\u00a02 diabetes mellitus is correlated with systemic atherosclerosis. Statin therapies have been proved to reduce low\u2010density lipoprotein cholesterol (LDL\u2010C) level, protecting type\u00a02 diabetes mellitus patients from cardiovascular events. Recently, more interest has been focused on the regression of lower extremity atherosclerotic disease (LEAD) for the potential prevention of amputation. However, the effects of pitavastatin and atorvastatin on LEAD in type\u00a02 diabetes mellitus patients have not been directly compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This study compared the effects of pitavastatin and atorvastatin on femoral total plaque areas (FTPA), and lipids and glucose metabolism in type\u00a02 diabetes mellitus patients with elevated LDL\u2010C level and LEAD. Type\u00a02 diabetes mellitus patients with LDL\u2010C level &gt;2.6\u00a0mmol\/L and LEAD were randomly assigned to receive either pitavastatin 2\u00a0mg\/day or atorvastatin 10\u00a0mg\/day for 48\u00a0weeks. FTPA were measured at baseline and the end of the study. Levels of glucose and lipids profile were measured periodically. The efficacy was evaluated in 63 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The percentage change in FTPA measurements was similar between the pitavastatin group and atorvastatin group (\u221217.79\u00a0\u00b1\u00a021.27% vs \u221214.34\u00a0\u00b1\u00a016.33%), as were the changes in LDL\u2010C (\u221244.0\u00a0\u00b1\u00a018.0% vs \u221240.3\u00a0\u00b1\u00a018.2%) and triglyceride (17.6\u00a0\u00b1\u00a020.0% vs 16.2\u00a0\u00b1\u00a017.0%). However, the level of high\u2010density lipoprotein cholesterol was significantly higher in the pitavastatin group compared with the atorvastatin group after 48\u00a0weeks of treatment (12.9\u00a0\u00b1\u00a010.3% vs 7.2\u00a0\u00b1\u00a011.7%, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). There were no significant differences between groups for the measurements of glucose metabolism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In type\u00a02 diabetes mellitus patients with elevated LDL\u2010C level and LEAD, 48\u00a0weeks of treatment with either pitavastatin or atorvastatin was associated with significant regression of FTPA. Pitavastatin treatment resulted in a significantly higher high\u2010density lipoprotein cholesterol level compared with atorvastatin treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.13472","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T21:44:01Z","timestamp":1606945441000},"page":"1278-1286","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Forty\u2010eight\u00a0weeks of statin therapy for type\u00a02 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas"],"prefix":"10.1111","volume":"12","author":[{"given":"Xieda","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-7072","authenticated-orcid":false,"given":"Liting","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangmeng","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-760X","authenticated-orcid":false,"given":"Yanbing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-7032","authenticated-orcid":false,"given":"Xiaopei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The First Affiliated Hospital of Sun Yat\u2010sen University Guangzhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61249-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867053363009"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.11.6.464"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1985.tb02853.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.305"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.02.064"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2018.07.006"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03390160062027"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.05.017"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2017.12.015"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2017.04.048"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/ejvs.2002.1611"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000090686.57897.F5"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00904-1"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.7.1758"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.06.055"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3717"},{"key":"e_1_2_7_19_1","first-page":"251","article-title":"Clinical efficacy of pitavastatin, a new 3\u2010hydroxy\u20103\u2010methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose\u2010finding study using the double\u2010blind, three\u2010group parallel comparison","volume":"52","author":"Saito Y","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000343145"},{"key":"e_1_2_7_21_1","first-page":"S1","article-title":"Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter\u2010Society Consensus (TASC)","volume":"31","author":"Dormandy JA","year":"2000","journal-title":"J Vasc Surg"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.8.1433"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2482-12-S1-S15"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000034508.55617.65"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.12.205"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-14-85"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2004.08.027"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000121505.88326.d2"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-008-0043-x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.04.017"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-09-0358"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.5405"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P002816"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.13.108"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.09.122"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.04.043"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.17210"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.E532"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-015935"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-017-0213-8"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13472","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.13472","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T18:15:04Z","timestamp":1693332904000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.13472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/jdi.13472"],"URL":"https:\/\/doi.org\/10.1111\/jdi.13472","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,30]]},"assertion":[{"value":"2020-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}